Previous 10 | Next 10 |
- Conference Call Scheduled May 12, 2020 at 4:30 p.m. ET - - Following Recent Financing Cash Runway to End of 2022 - BERKELEY HEIGHTS, N.J., May 12, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Com...
Cyclacel Pharmaceuticals (NASDAQ: CYCC), a biopharmaceutical company developing innovative medicines based on cancer cell biology, has closed a public offering of (i) 4,000,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and (ii) common warrants...
BERKELEY HEIGHTS, N.J., May 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2020 financial results on...
In what’s likely to be another wild week, penny stocks remain a focus. Over the past 8 trading days, oil and gas stocks that once traded above $5 saw many fall far below that threshold. They’ve actually become penny stocks. This was the latest sector to feel the burn of the cor...
BERKELEY HEIGHTS, N.J., April 24, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the clo...
Gainers: TORM (NASDAQ: TRMD ) +328% . More news on: TORM plc, Energous Corporation, SandRidge Energy, Inc., Stocks on the move, , Read more ...
Cyclacel Pharmaceuticals (NASDAQ: CYCC ) -53% on equity offering . More news on: Cyclacel Pharmaceuticals, Inc., Summit Wireless Technologies, Inc., Sibanye Stillwater Limited, Stocks on the move, , Read more ...
Thinly traded nano cap Cyclacel Pharmaceuticals (NASDAQ: CYCC ) craters 52% premarket on robust volume in reaction to its public offering of 4M common shares at $5 per share, each with an accompanying five-year warrant to purchase one common share at $5. More news on: Cyclace...
BERKELEY HEIGHTS, N.J., April 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the pri...
Gainers: Cyclacel Pharmaceuticals (NASDAQ: CYCC ) +91% . More news on: Cyclacel Pharmaceuticals, Inc., Benitec Biopharma Limited, VBI Vaccines Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Cyclacel Pharmaceuticals Inc. Company Name:
CYCC Stock Symbol:
NASDAQ Market:
Cyclacel Pharmaceuticals Inc. Website:
BERKELEY HEIGHTS, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the receipt of a notice from the European ...
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”...
- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;...